First human test for potential liver disease drug begins
NCT ID NCT07229911
Summary
This is an early-stage study to check the safety of a new drug called TAK-781. It will first be given to healthy volunteers to see how their bodies handle it. Then, a single dose will be given to a small group of people with a specific chronic liver disease called primary sclerosing cholangitis (PSC) to look for initial safety signals and effects on disease markers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON
RECRUITINGSalt Lake City, Utah, 84124, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.